The NIH BRAIN Initiative supports first in human, U.S. Food and Drug Administration (FDA) regulated clinical trials of novel invasive and non-invasive technologies to address disorders of the central nervous system, including neurological, neuropsychiatric, and sensory conditions. These investigational trials must also address circuit level activation of the central nervous system and typically involve closed-loop sensing and stimulating technology. Conditions under investigation include Parkinson’s disease, epilepsy, depression, stroke, tremor, visual loss, deafness, and paralysis, among others.
Theresa Cruz, Ph.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Nick Langhals, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)